Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6RQXB)

Drug Name
CNTO-6785 Drug Info
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM6RQXB

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 17 receptor (IL17R) TT69OHW I17RA_HUMAN; I17RB_HUMAN; I17RC_HUMAN; I17RD_HUMAN; I17RE_HUMAN Not Available [2]
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Not Available [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-17 (IL17) DTT IL17A 5.188 3.828 3.329 4.615
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Synovial tissue
The Studied Disease Rheumatoid arthritis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-17 (IL17) DTT IL17A 2.91E-02 -0.16 -0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01909427) An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.